The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Accelerated-phase MPNs: pathophysiology, treatment approaches and ongoing clinical trials
Anand Patel, MD, University of Chicago, Chicago, IL, discusses a recently published review on accelerated phase (AP) or blast phase (BP) myeloproliferative neoplasms (MPNs). Dr Patel summarizes the clinical and molecular risk factors for MPN progression and discusses conventional treatment approaches, such as intensive chemotherapy, hypomethylating agent (HMA)-based therapy, and HMA-venetoclax combination therapy. Additionally, Dr Patel discusses strategies being explored for patients with ASXL1-mutated disease, TP53-mutated disease, and IDH-mutated disease, including magrolimab and IDH inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
